1.Enzymatic properties of human aminopeptidase A. Regulation of its enzymatic activity by calcium and angiotensin IV.
Goto Y;Hattori A;Ishii Y;Mizutani S;Tsujimoto M J Biol Chem. 2006 Aug 18;281(33):23503-13. Epub 2006 Jun 21.
Aminopeptidase A (APA) is a type II membrane-bound protein implicated in the regulation of blood pressure in the brain renin-angiotensin system. In this study, a recombinant soluble form of APA was expressed in a baculovirus system, purified to homogeneity, and characterized. By using synthetic substrates, it was shown that although the enzyme has a rather broad substrate specificity in the absence of Ca2+, the preferential release of acidic amino acid residues was observed in the presence of Ca2+. Moreover, Ca2+ up- or down-regulated the enzymatic activity depending on the substrate. By searching for natural substrates of APA, we found that peptides having acidic amino acids at their N terminus (angiotensin II, neurokinin B, cholecystokinin-8, and chromogranin A) were cleaved by the enzyme efficiently in the presence but not in the absence of Ca2+. Moreover kallidin (Lys-bradykinin) was converted to bradykinin effectively only in the absence of Ca2+. These results suggest that Ca2+ increases the preference of the enzyme for the peptide substrates having N-terminal acidic amino acids. In addition, we found that angiotensin IV could bind to APA both in the presence and absence of Ca2+ and inhibited the enzymatic activity of APA competitively, suggesting that angiotensin IV acts as a negative regulator of the enzyme once generated from angiotensin II by the serial actions of aminopeptidases.
2.A comparison of the concentration-dependent actions of thyrotropin-releasing hormone, angiotensin II, bradykinin, and Lys-bradykinin on cytosolic free calcium dynamics in rat anterior pituitary cells: selective effects of dopamine.
Kuan SI;Login IS;Judd AM;MacLeod RM Endocrinology. 1990 Oct;127(4):1841-8.
Using Indo-1 as a fluorescent probe, we studied the dynamics and the underlying mechanisms of the response of cytosolic free calcium ([Ca2+]i) to different concentrations of four prolactin secretagogues, thyrotropin-releasing hormone, angiotensin II, bradykinin, and lys-bradykinin in rat anterior pituitary cells. Low concentrations (1-100 pM) of these peptides caused a sustained increase in [Ca2+]i, whereas high concentrations (up to 100 nM) caused a large transient elevation of [Ca2+]i that was followed by a lower sustained plateau. Experiments with protein kinase C-depleted cells suggested that phorbol diester-sensitive protein kinase C was not involved in the transition of [Ca2+]i from spike to plateau seen with high concentrations of secretagogue. Specific concentrations of secretagogue mobilized different pools of [Ca2+]i, as indicated by experiments with Ca2(+)-depleted medium. Low concentrations of secretagogue induced a Ca2+ response that was abolished by Ca2(+)-depleted medium, whereas high concentrations generated a [Ca2+]i response that was refractory to Ca2(+)-depleted medium. Dopamine (100 nM) abolished the [Ca2+]i plateau response to all four agents at low concentrations and selectively reduced the plateau component of the responses elicited at high concentrations of secretagogue.
3.Detection of bradykinin B1 receptors in rat aortic smooth muscle cells.
Schaeffer P;Laplace MC;Savi P;Prabonnaud V;Salel V;Herbert JM Biochem Pharmacol. 2001 Feb 1;61(3):291-8.
The tritiated bradykinin B1 receptor agonist [3H]des-Arg(10)-kallidin bound to a single class of high-affinity binding sites (K(d) = 0.5 +/- 0.16 nM; B(max) = 15,000 +/- 8,000 sites/cell) on cultured rat aortic smooth muscle cells. [3H]Des-Arg(10)-kallidin association and dissociation kinetics were monoexponential, making it possible to determine the association and dissociation rate constants (k(+1) = 1.5 10(5) M(-1) sec(-1); k(-1) = 4.2 10(-5) sec(-1)). [3H]Des-Arg(10)-kallidin binding was inhibited by specific ligands of bradykinin B1 and B2 receptors with a rank order of potency consistent with that known for bradykinin B1 receptors in other species (des-Arg(9)-[Leu(8)]bradykinin = des-Arg(10)-kallidin = des-Arg(9)-bradykinin = des-Arg(10)-[Leu(9)]kallidin > des-Arg(10)-HOE-140 >> bradykinin >> HOE-140). Bradykinin B1 receptor mRNA was also detected in these cells. Des-Arg(10)-kallidin increased cytosolic free Ca2+ levels, phosphoinositide turnover, and arachidonic acid release at nanomolar concentrations (respective EC(50) values: 16 +/- 2, 4 +/- 2.7, 6 +/- 2 nM). These functional effects of des-Arg(10)-kallidin could be blocked by the bradykinin B1 receptor antagonist des-Arg(9)-[Leu(8)]bradykinin, but were not sensitive to bradykinin B2 receptor antagonists.